Back

Genetic and pharmacologic modulation of RAGE rescues the diabetes-mediated impairments to bone at multiple length scales

Broz, K. S.; Hung, T.; Walk, R. E.; LoTempio, S.; Flores, K. M.; Tang, S. Y.

2026-04-06 bioengineering
10.64898/2026.04.02.716153 bioRxiv
Show abstract

The bone matrix is precisely maintained and optimized to resist fractures. However, aging and disease deteriorate the bone matrix and increase fragility. Individuals with type 2 diabetes (T2D) have an elevated risk of bone fracture despite apparently normal bone mass. The chronic hyperglycemia in T2D promotes the formation of advanced glycation end-products (AGEs) in the bone tissue and modify the matrix mechanics. AGEs also bind to its receptor, RAGE, to activate inflammation and alter homeostasis. Using a leptin-receptor deficient mouse model of diabetes, we used a combination of high-resolution methods across multiple scales to evaluate the microarchitectural-, material- and cellular- level changes affected by the modulation of RAGE. To demonstrate the relevance of RAGE, we genetically ablated RAGE (RAGE-null) before the onset of diabetes; and to demonstrate the potency of RAGE as a disease modifying therapy, a RAGE antagonist (FPS-ZM1) was administered after prolonged diabetes. Diabetes impaired bone microstructure, the homeostatic actions of bone cells, the bone matrix nanomechanics, and whole- bone strength. The constitutive ablation of RAGE in diabetic animals prevented AGEs accumulation and the decline of trabecular connectivity; protected against the loss of osteocyte lacunae density and morphology; and maintained the matrix nanomechanics and bone strength. The inhibition of RAGE after the onset of diabetes reversed AGE accumulation and loss of bone volume; rescued osteocyte lacunae density and osteoclast activity; and restored matrix nanomechanics and bone strength. These results suggest that RAGE is a viable therapeutic target for diabetes-mediated impairments of bone quality. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=129 SRC="FIGDIR/small/716153v1_ufig1.gif" ALT="Figure 1000"> View larger version (26K): org.highwire.dtl.DTLVardef@6d8a5borg.highwire.dtl.DTLVardef@1967b5borg.highwire.dtl.DTLVardef@7cb1edorg.highwire.dtl.DTLVardef@85491d_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
eLife
5422 papers in training set
Top 3%
12.5%
2
Advanced Science
249 papers in training set
Top 1%
10.1%
3
Aging Cell
144 papers in training set
Top 0.9%
6.4%
4
JBMR Plus
16 papers in training set
Top 0.1%
6.4%
5
Cell Reports
1338 papers in training set
Top 9%
4.9%
6
Acta Biomaterialia
85 papers in training set
Top 0.2%
4.3%
7
Journal of Bone and Mineral Research
32 papers in training set
Top 0.1%
4.0%
8
Science Advances
1098 papers in training set
Top 5%
3.6%
50% of probability mass above
9
iScience
1063 papers in training set
Top 5%
3.6%
10
Nature Communications
4913 papers in training set
Top 39%
3.6%
11
Advanced Healthcare Materials
71 papers in training set
Top 0.8%
2.6%
12
Developmental Cell
168 papers in training set
Top 6%
2.6%
13
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 32%
1.7%
14
Bone
22 papers in training set
Top 0.2%
1.7%
15
JCI Insight
241 papers in training set
Top 4%
1.5%
16
Scientific Reports
3102 papers in training set
Top 64%
1.3%
17
Progress in Neurobiology
41 papers in training set
Top 1%
1.2%
18
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.2%
19
Communications Biology
886 papers in training set
Top 18%
0.9%
20
Cell Systems
167 papers in training set
Top 10%
0.9%
21
The FASEB Journal
175 papers in training set
Top 2%
0.9%
22
Cancer Research
116 papers in training set
Top 3%
0.8%
23
Computational and Structural Biotechnology Journal
216 papers in training set
Top 8%
0.8%
24
Osteoarthritis and Cartilage
30 papers in training set
Top 0.4%
0.7%
25
Advanced Functional Materials
41 papers in training set
Top 2%
0.6%
26
Science Translational Medicine
111 papers in training set
Top 7%
0.6%